Patients in England will be among those who are first to benefit from Sanofi and Regeneron’s new cancer immunotherapy Libtayo, after NICE recommended funding for a form of skin cancer immediately after European approval. In a bid to bring cancer d...
Original Article: Immediately after EU nod, England's NHS funds Sanofi skin cancer drug